Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01460368 · ClinicalTrials.gov registry record · Phase 1

A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart

A Phase 1 study, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 1
Development phase
67
Enrollment target

NCT01460368 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 67 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01460368, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 1
Development phase
67 participants
Enrollment target

Study Summary

Part A: The purpose of Part A of the study is to look at the electrocardiogram (ECG) effects due to blood sugar changes after a meal compared to when LY2409021 is also given with a meal. Part B: The purpose of Part B is to evaluate the effect of LY2409021, when given at a dose level much higher than what would normally be given, on the electrical activity of the heart as measured by ECG in relation to placebo and moxifloxacin.

Interventions

  • DRUG Placebo
  • DRUG Moxifloxacin
  • DRUG LY2409021

Trial Details

FieldValue
Enrollment Target 67 participants
Start Date 2011-10
Est. Completion 2012-03
Phase Phase 1

Sponsor

Eli Lilly and Company

1,341 total trials

What the Registry Record Tells You About NCT01460368

The ClinicalTrials.gov registry entry for NCT01460368 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT01460368 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01460368 about?

NCT01460368 is a clinical study titled "A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart". Part A: The purpose of Part A of the study is to look at the electrocardiogram (ECG) effects due to blood sugar changes after a meal compared to when LY2409021 is also given with a meal. Part B: The purpose of Part B is to evaluate the effect of LY2409021, when given at a dose level much higher tha...

What is the current status of trial NCT01460368?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2011-10. Estimated completion is 2012-03.

What interventions are being tested in trial NCT01460368?

The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), LY2409021 (DRUG).

Who is sponsoring clinical trial NCT01460368?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.